Brookfield Asset Management Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Brookfield Asset Management Inc.

  • $14 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 16, 2021
BUY
$21.26 - $38.85 $291,049 - $531,856
13,690 Added 46.38%
43,204 $1.27 Million
Q2 2021

Aug 17, 2021
BUY
$12.56 - $29.69 $66,078 - $156,199
5,261 Added 21.69%
29,514 $756,000
Q1 2021

May 17, 2021
SELL
$12.37 - $17.74 $149,701 - $214,689
-12,102 Reduced 33.29%
24,253 $332,000
Q4 2020

Feb 16, 2021
BUY
$9.82 - $18.27 $357,006 - $664,205
36,355 New
36,355 $602,000

Others Institutions Holding CERE

# of Institutions
8
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Brookfield Asset Management Inc. Portfolio

Follow Brookfield Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brookfield Asset Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email